Physician profile

Dan Qu

Miami, FL

NPI 1780334508

$253.66

in general payments reported to CMS, 2019-2025

8 companies · $254 in 2025

The $254 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$253.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $50.63 2025
Emd Serono, INC. $47.67 2025
Eisai INC. $43.50 2025
Astrazeneca Pharmaceuticals Lp $26.53 2025 Calquence
Jazz Pharmaceuticals INC. $24.49 2025
Pharmaessentia USA Corporation $22.70 2025 Besremi
Daiichi Sankyo INC. $20.81 2025 Enhertu
Glaxosmithkline, LLC. $17.33 2025 Ojjaara

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dan Qu

$253.66

in general payments reported 2019-2025

Years
2025
Top company
Pfizer INC.
Context
The $254 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11949241/dan-qu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.